Just before last year's trade talks in Cancun, the US made some concessions, so that it was no longer the only holdout. In its bilateral trade agreements, however, the US is demanding what is becoming known as "TRIPs plus," which would strengthen intellectual property rights further, to ensure that countries only have the right to produce inexpensive generic drugs during epidemics and other emergencies.